Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

Launched by ERASME UNIVERSITY HOSPITAL · Dec 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the role of a specific marker called Fibroblast Activation Protein (FAP) in patients with fibrotic lung diseases, such as pulmonary fibrosis and idiopathic pulmonary fibrosis (IPF). The goal is to see how starting a new anti-fibrotic treatment affects the activity of lung fibrosis, which can be measured using a special imaging test called FAPI PET/CT. This trial is currently looking for participants between the ages of 65 and 74, regardless of gender, who have been diagnosed with a fibrotic lung disease.

To be eligible, participants must be adults with a confirmed diagnosis of either idiopathic pulmonary fibrosis or another type of fibrotic lung disease. However, pregnant or nursing women and individuals with significant other medical conditions that could affect their participation are not eligible. Participants in this trial can expect to receive the anti-fibrotic treatment and undergo imaging tests to monitor their lung condition. It’s important to note that this study aims to improve understanding of lung fibrosis and may help in developing better treatments for this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
• Exclusion Criteria:
• • Pregnant or nursing patients
• • Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
• • Patients with an active lung neoplasm or any active neoplasm for blood samples